191 related articles for article (PubMed ID: 20200430)
1. TP53, MDM2, NQO1, and susceptibility to cervical cancer.
Hu X; Zhang Z; Ma D; Huettner PC; Massad LS; Nguyen L; Borecki I; Rader JS
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):755-61. PubMed ID: 20200430
[TBL] [Abstract][Full Text] [Related]
2. Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma.
Singhal P; Hussain S; Thakur N; Batra S; Salhan S; Bhambani S; Bharadwaj M
DNA Cell Biol; 2013 Jan; 32(1):19-27. PubMed ID: 23210739
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in TP53 (rs1042522), p16 (rs11515 and rs3088440) and NQO1 (rs1800566) genes in Thai cervical cancer patients with HPV 16 infection.
Chansaenroj J; Theamboonlers A; Junyangdikul P; Swangvaree S; Karalak A; Chinchai T; Poovorawan Y
Asian Pac J Cancer Prev; 2013; 14(1):341-6. PubMed ID: 23534750
[TBL] [Abstract][Full Text] [Related]
4. Lack of evidence that proline homozygosity at codon 72 of p53 and rare arginine allele at codon 31 of p21, jointly mediate cervical cancer susceptibility among Indian women.
Bhattacharya P; Sengupta S
Gynecol Oncol; 2005 Oct; 99(1):176-82. PubMed ID: 16054204
[TBL] [Abstract][Full Text] [Related]
5. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.
Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N
Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146
[TBL] [Abstract][Full Text] [Related]
6. The preliminary study of p53 codon 72 polymorphism and risk of cervical carcinoma in Gabonese women.
Assoumou SZ; Boumba AL; Ndjoyi-Mbiguino A; Khattabi A; Ennaji MM
Med Oncol; 2015 Jan; 32(1):281. PubMed ID: 25502079
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism in exon 4 of TP53 gene associated to HPV 16 and 18 in Mexican women with cervical cancer.
Piña-Sánchez P; Hernández-Hernández DM; Taja-Chayeb L; Cerda-Flores RM; González-Herrera AL; Rodea-Avila C; Apresa-García T; Ostrosky-Wegman P; Vázquez-Ortíz G; Mendoza-Lorenzo P; Dueñas-González A; Salcedo M
Med Oncol; 2011 Dec; 28(4):1507-13. PubMed ID: 20661667
[TBL] [Abstract][Full Text] [Related]
8. Reduced rate of human papillomavirus infection and genetic overtransmission of TP53 72C polymorphic variant lower cervical cancer incidence.
Alsbeih GA; Al-Harbi NM; Bin Judia SS; Khoja HA; Shoukri MM; Tulbah AM
Cancer; 2017 Jul; 123(13):2459-2466. PubMed ID: 28393355
[TBL] [Abstract][Full Text] [Related]
9. [Correlation between mutation of p53 gene 2-4 exons from peripheral blood and HPV16 positive cervical cancer susceptibility and clinical significance].
Yin CM; Yao YF; Yan ZL; Yang HY
Zhonghua Fu Chan Ke Za Zhi; 2017 May; 52(5):320-326. PubMed ID: 28545270
[No Abstract] [Full Text] [Related]
10. Significant association between IL10-1082/-819 and TNF-308 haplotypes and the susceptibility to cervical carcinogenesis in women infected by Human papillomavirus.
Chagas BS; Lima RCP; Paiva Júnior SSL; Silva RCO; Cordeiro MN; Silva Neto JDC; Batista MVA; Silva AJD; Gurgel APAD; Freitas AC
Cytokine; 2019 Jan; 113():99-104. PubMed ID: 29935877
[TBL] [Abstract][Full Text] [Related]
11. No association between SNP309 promoter polymorphism in the MDM2 and cervical cancer in a study from northeastern Brazil.
Meissner Rde V; Barbosa RN; Fernandes JV; Galvão TM; Galvão AF; Oliveira GH
Cancer Detect Prev; 2007; 31(5):371-4. PubMed ID: 18023538
[TBL] [Abstract][Full Text] [Related]
12. MDM2 SNP 309 human papillomavirus infection in cervical carcinogenesis.
Nunobiki O; Ueda M; Yamamoto M; Toji E; Sato N; Izuma S; Okamoto Y; Torii K; Noda S
Gynecol Oncol; 2010 Sep; 118(3):258-61. PubMed ID: 20538323
[TBL] [Abstract][Full Text] [Related]
13. No relationship observed between human p53 codon-72 genotype and HPV-associated cervical cancer in a population group with a low arginine-72 allele frequency.
Govan VA; Loubser S; Saleh D; Hoffman M; Williamson AL
Int J Immunogenet; 2007 Jun; 34(3):213-7. PubMed ID: 17504512
[TBL] [Abstract][Full Text] [Related]
14. TP53 polymorphism, HPV infection, and risk of cervical cancer.
Klug SJ; Wilmotte R; Santos C; Almonte M; Herrero R; Guerrero I; Caceres E; Peixoto-Guimaraes D; Lenoir G; Hainaut P; Walboomers JM; Muñoz N
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):1009-12. PubMed ID: 11535556
[TBL] [Abstract][Full Text] [Related]
15. Effects of MDM2 promoter polymorphisms on the development of cervical neoplasia in a Southeastern Brazilian population.
Vargas-Torres SL; Portari EA; Klumb EM; Guillobel HC; Camargo MJ; Russomano FB; Macedo JM
Biomarkers; 2014 Dec; 19(8):637-45. PubMed ID: 25271042
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of GSTM1, p21, p53 and HPV infection with cervical cancer in Korean women.
Lee SA; Kim JW; Roh JW; Choi JY; Lee KM; Yoo KY; Song YS; Kang D
Gynecol Oncol; 2004 Apr; 93(1):14-8. PubMed ID: 15047208
[TBL] [Abstract][Full Text] [Related]
17. P53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women.
Roh JW; Kim BK; Lee CH; Kim J; Chung HH; Kim JW; Park NH; Song YS; Park SY; Kang SB
Oncol Res; 2010; 18(9):453-9. PubMed ID: 20524403
[TBL] [Abstract][Full Text] [Related]
18. Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma.
Ezzikouri S; Essaid El Feydi A; Afifi R; Benazzouz M; Hassar M; Pineau P; Benjelloun S
Int J Biol Markers; 2011; 26(4):229-33. PubMed ID: 22180176
[TBL] [Abstract][Full Text] [Related]
19. TP53 codon 72 polymorphism and risk for cervical cancer in Portugal.
Santos AM; Sousa H; Catarino R; Pinto D; Pereira D; Vasconcelos A; Matos A; Lopes C; Medeiros R
Cancer Genet Cytogenet; 2005 Jun; 159(2):143-7. PubMed ID: 15899386
[TBL] [Abstract][Full Text] [Related]
20. Polymorphism of TP53 codon 72 and the risk of cervical cancer among Korean women.
Kim JW; Roh JW; Park NH; Song YS; Kang SB; Lee HP
Am J Obstet Gynecol; 2001 Jan; 184(2):55-8. PubMed ID: 11174479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
